LIraglutide and Beta-cell RepAir (LIBRA) Study

NCT01270789 on ClinicalTrials.gov · last registry update 2014-09-12

A small phase 3 — 63 participants, against a typical 424. The sponsor logged completion for December 2013. Primary outcome, as filed: Preservation of beta-cell function measured by Insulin Secretion-Sensitivity Index-2 (ISSI-2). liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Mount Sinai Hospital, Canada
Sponsor type: Other
Enrollment: 63
Started: 2011-01
Primary completion: 2013-12 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Preservation of beta-cell function measured by Insulin Secretion-Sensitivity Index-2 (ISSI-2)

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.